In our study, which analyzed 2,408 phenotypes in the FinnGen R10 study (Francis et al., 2022), BCC emerged as the most significant phenotype associated with PTGES2 and RNASET2, affirming their reliability as biomarkers and therapeutic targets for BCC. The gene discussed is RNASET2; the disease is skin basal cell carcinoma.